The agreement creates a working relationship between the parties for the manufacturing development and current good manufacturing practice (cGMP) manufacture of the company’s lead novel therapeutic drug liposomal
The agreement formalizes interface pricing, implementation, and maintenance fees for customers wishing to use Iatric Systems interfaces between IntelliDOT solutions and a Meditech magic or Meditech client/server healthcare
This company is recognized worldwide as one of the innovators of cell and tissue engineering. Due to the sensitivity and competitive nature of this industry, the company has
The company has also announced an update of the data from the Phase II trial of palifosfamide used as a single agent in advanced sarcoma. The Phase I
The agreement includes an upfront payment by Codexis of $10 million provided that certain performance criteria are satisfied. Additional financial terms were not disclosed. Mark Emalfarb, founder and
The new system was designed, tested and approved for use with magnetic resonance imaging (MRI) under specified scanning conditions, and is now commercially available in select European countries.
This vaccine is being delivered using Inovio’s electroporation-based DNA delivery system. In the third and highest dose cohort of the study, two of three subjects demonstrated reductions in
Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones. Following authorization from
In the notice letter, Teva alleges that two of the patents associated with emtricitabine-owned by Emory University and licensed exclusively to Gilead Sciences are invalid, unenforceable and/or will
Ptolemy-2 is an international, multi-center clinical trial designed to assess the safety and efficacy of the Viacor Percutaneous Transvenous Mitral Annuloplasty (PTMA) system in heart failure patients. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.